ARS Pharma up after Japan's approval for allergic reaction nasal spray

** Drug developer ARS Pharmaceuticals' shares SPRY.O rise 7.7% to $10.69 premarket

** Company says Japan's health regulator has approved its nasal spray, neffy, in 1 mg and 2 mg doses, for emergency treatment of allergic reactions in adults and children weighing over 15 kg

** In 2020, ARS Pharma signed an exclusive licensing deal with Japan's Alfresa Holdings 2784.T, granting the company rights to commercialize its allergy treatment neffy in the country

** Alfresa expects neffy to be available in Q4 2025 - SPRY

** Up to last close, SPRY down 5.88% YTD